Perimenopause, Appetite, and Where a GLP-1 Fits

The body that stopped answering to the old rules

Somewhere in her forties, a woman often notices that the body she negotiated with for two decades has stopped honoring the deal. The same food, the same walk, the same restraint — and the weight settles differently, higher around the middle, more stubborn than it used to be. The instinct, drilled in by a lifetime of diet culture, is to read this as a personal failure of discipline. It is not. It is endocrinology — and the endocrinology turns out to be stranger and more specific than almost anyone tells you.

The scale is the wrong instrument

Start with the finding that should be common knowledge and is not. Researchers on the Study of Women's Health Across the Nation tracked women through the menopause transition with body-composition scans rather than a bathroom scale. Fat and lean mass were both rising before the transition began. At its start, the rate of fat gain doubled and lean mass began to fall, and those two trajectories continued until roughly two years after the final menstrual period. Total body weight, meanwhile, climbed at the same steady rate through premenopause and the transition — with no acceleration at all¹.

Read that twice, because it explains a decade of women being told they are imagining things. The instrument every woman reaches for is measuring the one variable that did not change. Muscle was leaving and fat was arriving at double speed, and the number under her feet stayed on its old trend line.

What changed was where the fat went. A second SWAN analysis followed 380 women with repeated DXA scans over a median of 11.8 years and found android fat — the fat that sits around the middle — rising 1.21% a year during premenopause and 5.54% a year during the transition. Visceral fat, flat until then, started climbing at 6.24% a year². The authors' closing line is the one to carry out of the paper: waist and hip circumferences are less sensitive to this redistribution than the scan is. The tape measure under-reports it too.

What women actually describe

The lived version of that data has been documented, and it is worth reading in the researchers' own restrained language. In a qualitative study run out of Technological University of the Shannon, seventeen perimenopausal women in Ireland — average age 50.6 — sat for semi-structured interviews about weight and body shape. Participants described an experience of weight and body shape that was different from any previous experience they had had, and were, in the authors' phrase, "attempting to make sense of body shape and weight variations," with body image often negatively affected. Women in the study wanted to make lifestyle changes and were motivated to; the symptoms and competing life demands of exactly those years kept getting in the way. The paper's conclusion is that women are seeking guidance to navigate this and not finding it³.

That is the gap the numbers predict: a body doing something real and measurable, and a woman with no framework for it except the one she inherited, which says this is her fault.

Your forty-something body is not betraying you out of laziness. It is keeping an appointment with your endocrinology.

Where a GLP-1 enters the picture

This is the backdrop against which many women first consider a GLP-1, and it is a reasonable one. The medications act on appetite directly, and the size of that effect is not subtle. In a 20-week randomized trial in 72 adults with obesity, energy intake at an ad libitum lunch was 35% lower on semaglutide 2.4 mg than on placebo — 1,736 kJ against 2,676 kJ. Hunger and prospective food consumption fell, fullness and satiety rose, and the Control of Eating Questionnaire showed fewer and weaker food cravings. Body weight fell 9.9% on semaglutide and 0.4% on placebo⁴.

Nor is it a two-week flash. STEP 5 randomized 304 adults to semaglutide 2.4 mg or placebo and followed them for two years, assessing efficacy across everyone randomized regardless of whether they stopped the drug. Mean weight change at week 104 was −15.2% on semaglutide versus −2.6% on placebo, and 77.1% versus 34.4% lost at least 5%⁵. For a transition that itself unfolds over years, a treatment measured in years is at least the right shape of tool.

There is a quiet detail in that trial worth naming: 77.6% of STEP 5's participants were women, with a mean age of 47.3 — the exact demographic center of this article. But the trial reported nothing by menopausal status. A perimenopausal woman reading it is reading about people like herself without ever being told so.

Marketing has noticed the gap even where the trials have not: Eve builds its pitch explicitly around women's health rather than weight loss in general, at a flat $195/mo for its compounded program. That positioning is worth knowing about, though it does not come with any menopause-specific guidance beyond what its peers publish.

What the menopause research does — and does not — say

It would be easy, and wrong, to write that nobody has studied this. Somebody has. A 2026 scoping review searched the literature specifically for GLP-1 receptor agonists in menopausal and postmenopausal women and found that across the available studies the drugs were associated with greater weight loss and a decrease in central adiposity in this group, with a smaller number of studies also reporting improved vasomotor symptoms and cardiovascular markers⁶.

The same authors open by stating plainly that the effects in this population "are not well characterized and may differ from other patient populations, given their different hormone profiles," and close by calling for larger studies on cardiovascular markers and bone density⁶. So the honest summary is not an absence. It is a direction — encouraging, and pointed squarely at the central adiposity the SWAN data identify as the real change — resting on an evidence base thinner than the prescribing volume.

Holding two truths at once

None of this makes a GLP-1 the automatic answer to perimenopause. It is a serious medication, the menopause-specific research is genuinely behind the demand, and appetite is one thread in a transition that also touches sleep, mood, bone, and heart — bone especially, given that these same years are already taking lean mass. The honest position holds two truths together: your forty-something body is not betraying you out of laziness, and a medication is one option among several, alongside strength training, sleep, and a clinician who takes the whole transition seriously rather than the one number that was never measuring it.

That last clause is the hard one to buy, because most weight-loss telehealth is not built to treat a transition. It is built to treat a number, and it will prescribe against that number without ever asking what is moving it. Two programs on our board are exceptions, and they fail in opposite directions. WeightWatchers Clinic runs a menopause line where a clinician can prescribe hormone therapy alongside the weight work rather than instead of it, wrapped in thirty years of behavioral programming — and then sells it as a six- or twelve-month term you cannot leave early. Evernow is a menopause practice first, and will put a GLP-1 and hormone therapy on one plan in all fifty states with nothing to schedule — and publishes no cancellation policy at all, nor what discipline its clinicians hold. The reservations are in both reviews and neither is small. But these are the two programs we cover that treat this transition as a clinical fact rather than a marketing segment, which is worth knowing even if you take the idea to your own doctor instead.